Medical costs averted by HIV prevention efforts in the United States, 1991-2006

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 5, 2010, Pages 565-567

  Farnham, Paul G ^a   Holtgrave, David R ^b   Sansom, Stephanie L ^a   Hall, H Irene ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

COST; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; DISEASE TRANSMISSION; EXERCISE; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; UNITED STATES;

COMMUNICABLE DISEASE CONTROL; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; UNITED STATES;

EID: 77955002187     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e461b2     Document Type: Letter

References (17)

1. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993;270:474-478.
2. Guinan ME, Farnham PG, Holtgrave DR. Estimating the value of preventing a human immunodeficiency virus infection. Am J Prev Med. 1994;10:1-4.
3. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr. 1997;16:54-62.
4. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care. 2006;44:990-997.
5. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-823.
6. HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquire Immune Defic Syndr. 2002;30:21-26.
7. Holtgrave DR. Estimating the effectiveness and efficiency of US HIV prevention efforts using scenario and cost-effectiveness analysis. AIDS. 2002;16:2347-2349.
8. Holtgrave DR. Written testimony on HIV/AIDS incidence and prevention for the U.S. House of Representatives Committee on Oversight and Government Reform, September 16, 2008. Available at: http://oversight.house.gov/documents/ 20080916115223.pdf. Accessed September 16, 2009.
9. Holtgrave DR, Hall HI, Rhodes PH, et al. Updated annual HIV transmission rates in the United States, 1977-2006. J Acquir Immune Defic Syndr. 2009;50:236-238.
10. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520-529.
11. Campsmith ML, Rhodes PH, Hall HI, et al. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53:619-624.
12. Henry J. Kaiser Family Foundation. The Global HIV/AIDS Epidemic. HIV/AIDS Policy Fact Sheet. July 2008. Available at: http://www. kff.org/hivaids. Accessed October 22, 2009.
13. Holtgrave DR. Apparent declines in the global HIV transmission rate. Int J STD AIDS. 2009; 20:876-878.
14. Joint United Nations Programme on HIV/AIDS/World Health Organization. Q&A on HIV/AIDS estimates: understanding the latest estimates of the 2008 Report on the global AIDS epidemic. July 2008. Availabe at: http://www.unaids. org. Accessed October 25, 2009.
15. Ghys PD, Walker N, McFarland W, et al. Improved data, methods and tools for the 2007 HIV and AIDS estimates and projections. Sex Transm Infect. 2008;84(Suppl I):i1-i4.
16. U.S. Bureau of Labor Statistics. Consumer Price Index. CPI Detailed Report Tables. Available at: http://www.bls.gov/cpi/. Accessed November 15, 2009.
17. Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:451-457.